Latest Insider Transactions at X4 Pharmaceuticals, Inc (XFOR)
This section provides a real-time view of insider transactions for X4 Pharmaceuticals, Inc (XFOR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of X4 Pharmaceuticals, Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of X4 Pharmaceuticals, Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 15
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,724
-1.21%
|
$13,448
$2.23 P/Share
|
|
Jun 15
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,417
-5.78%
|
$10,834
$2.22 P/Share
|
|
Jun 13
2023
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
Jun 13
2023
|
Gary Bridger Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
Jun 13
2023
|
David W J Mcgirr Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
Jun 13
2023
|
Francoise De Craecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
Jun 13
2023
|
Michael S Wyzga Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
Jun 13
2023
|
Alison Frances Lawton Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+46.55%
|
-
|
|
May 31
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,292
-1.12%
|
$6,292
$1.95 P/Share
|
|
Mar 10
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52,500
-35.91%
|
$0
$0.84 P/Share
|
|
Mar 10
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
18,192
-10.64%
|
$0
$0.84 P/Share
|
|
Mar 10
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
49,678
-8.1%
|
$0
$0.84 P/Share
|
|
Mar 10
2023
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
16,806
-16.29%
|
$0
$0.84 P/Share
|
|
Feb 13
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
21,695
-3.42%
|
$0
$0.93 P/Share
|
|
Feb 13
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,721
-15.94%
|
$0
$0.93 P/Share
|
|
Feb 13
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,348
-2.48%
|
$0
$0.93 P/Share
|
|
Feb 13
2023
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
928
-0.89%
|
$0
$0.93 P/Share
|
|
Aug 17
2022
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
13,448
-2.07%
|
-
|
|
Aug 17
2022
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,834
-5.86%
|
-
|
|
Aug 17
2022
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,334
-5.43%
|
-
|
|
Aug 17
2022
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,713
-0.95%
|
-
|
|
Jun 30
2022
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,578
-0.87%
|
-
|
|
Jun 30
2022
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,641
-1.41%
|
-
|
|
Jun 24
2022
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,166
-2.64%
|
-
|
|
Jun 24
2022
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,724
-1.03%
|
-
|
|
Jun 24
2022
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
856
-0.47%
|
-
|
|
Jun 24
2022
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,416
-2.81%
|
-
|
|
Jun 16
2022
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,166
-2.57%
|
-
|
|
Jun 16
2022
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
856
-0.47%
|
-
|
|
Jun 16
2022
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,724
-1.02%
|
-
|
|
Jun 16
2022
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,416
-2.73%
|
-
|
|
Jun 06
2022
|
David W J Mcgirr Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
Murray Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
Francoise De Craecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
Michael S Wyzga Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
Alison Frances Lawton Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 06
2022
|
Gary Bridger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,667
+50.0%
|
-
|
|
Jun 03
2022
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,292
-0.94%
|
$6,292
$1.21 P/Share
|
|
Mar 01
2022
|
Derek M Meisner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+39.35%
|
-
|
|
Mar 01
2022
|
Diego Cadavid Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,000
+48.23%
|
-
|
|
Mar 01
2022
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+34.63%
|
-
|
|
Mar 01
2022
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,000
+48.23%
|
-
|
|
Mar 01
2022
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
220,789
+24.84%
|
-
|
|
Mar 01
2022
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+36.47%
|
-
|
|
Feb 11
2022
|
Diego Cadavid Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
928
-11.55%
|
-
|
|
Feb 11
2022
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
21,695
-4.63%
|
-
|
|
Feb 11
2022
|
Arthur Taveras Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
928
-11.55%
|
-
|
|
Feb 11
2022
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,545
-13.87%
|
-
|
|
Feb 11
2022
|
Derek M Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,909
-21.87%
|
-
|